Business
OmniAb Introduces the xPloration® Partner Access Program
EMERYVILLE, Calif., May 08, 2025--OmniAb, Inc. (NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb’s proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.
About this update from Omniab, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":308,"url":"https://media.zenfs.com/en/business-wire.com/d8cb6f9e4b8e163542282d24f3c72ed2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QD_CgGyHFOkEijeiq8CEug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYxNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d8cb6f9e4b8e163542282d24f3c72ed2","width":480,"height":308}},"lazy":false},{"type":"text","content":"High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb’s Partners for Use in Their Own Laboratories","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"EMERYVILLE, Calif., May 08, 2025--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb’s proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.","length":464,"tagName":"p","attribs":{}},{"type":"text","content":""xPloration has been a core part of our company’s discovery workflow for several years and our partners are increasingly recognizing its substantial value. Following multiple inbound inquiries and extensive testing and validation, the instrument and proprietary single-use consumables are now ready for sale to current partners for use within their own laboratories," said Matt Foehr, Chief Executive Officer of OmniAb.","length":429,"tagName":"p"},{"type":"text","content":""xPloration represents a significant advancement in single B-cell screening and antibody discovery. It provides important advantages in the speed and quality of throughput due to its superior processing speed, exceptional hit recovery, unparalleled ease-of-use and reliability," he added. "This launch to our growing base of nearly 100 partners via the xPloration Partner Access Program increases the reach of our business and also adds new revenue streams to OmniAb, while furthering our mission of pushing the frontiers of discovery technologies."","length":569,"tagName":"p"},{"type":"text","content":"xPloration leverages c...